Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus
Circulation2017Vol. 136(12), pp. 1167–1169
Citations Over TimeTop 10% of 2017 papers
Kristina Striepe, Agnes Jumar, Christian Ott, Marina V. Karg, Markus P. Schneider, Dennis Kannenkeril, Roland E. Schmieder
Related Papers
- → Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling(2020)39 cited
- → Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus(2019)31 cited
- → Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control(2018)24 cited
- → Update on SGLT2 Inhibitors—New Data Released at the American Diabetes Association(2017)20 cited
- → Comprehensive List of DACA Drugs(1968)